Trial Profile
Efficacy and safety of the combination of crizotinib and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer harboring EML4-ALK fusion variant mutation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology